E A Eisenhauer

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. ncbi Trial design for testing new therapies in ovarian cancer
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 15:258-65. 2005
  2. doi Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting
    E A Eisenhauer
    NCIC Clinical Trials Group, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:74-5. 2008
  3. doi New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Queen s University, Kingston, Ontario, Canada
    Eur J Cancer 45:228-47. 2009
  4. ncbi Impact of new non-cytotoxics in the treatment of ovarian cancer
    E Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, Canada
    Int J Gynecol Cancer 11:68-72. 2001
  5. ncbi Phase I clinical trial design in cancer drug development
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    J Clin Oncol 18:684-92. 2000
  6. doi A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
  7. doi Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
    J I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
    Ann Oncol 22:2403-10. 2011
  8. ncbi The taxoids. Comparative clinical pharmacology and therapeutic potential
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Drugs 55:5-30. 1998
  9. ncbi Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study
    C Cripps
    Ottawa Regional Cancer Centre, Ontario, Canada
    Ann Oncol 10:1175-9. 1999
  10. doi Optimal assessment of response in ovarian cancer
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Ann Oncol 22:viii49-viii51. 2011

Collaborators

Detail Information

Publications21

  1. ncbi Trial design for testing new therapies in ovarian cancer
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 15:258-65. 2005
  2. doi Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting
    E A Eisenhauer
    NCIC Clinical Trials Group, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:74-5. 2008
  3. doi New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Queen s University, Kingston, Ontario, Canada
    Eur J Cancer 45:228-47. 2009
    ..Imaging guidance: the revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions...
  4. ncbi Impact of new non-cytotoxics in the treatment of ovarian cancer
    E Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, Canada
    Int J Gynecol Cancer 11:68-72. 2001
    ....
  5. ncbi Phase I clinical trial design in cancer drug development
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    J Clin Oncol 18:684-92. 2000
    ....
  6. doi A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
    ..Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent epithelial ovarian cancer...
  7. doi Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
    J I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
    Ann Oncol 22:2403-10. 2011
    ..Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity. The clinical validation of BRCA1 as a prognostic marker in OC remains unresolved...
  8. ncbi The taxoids. Comparative clinical pharmacology and therapeutic potential
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Drugs 55:5-30. 1998
    ..It will be some years yet before taxoid-based combinations have been evaluated sufficiently in randomised trials such that the impact of this novel class can be adequately assessed in terms of survival and cure rates...
  9. ncbi Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study
    C Cripps
    Ottawa Regional Cancer Centre, Ontario, Canada
    Ann Oncol 10:1175-9. 1999
    ..This trial has evaluated the effects of LY231514 (Multitargeted antifolate (MTA)) given to previously untreated patients with recurrent or metastatic colorectal carcinoma...
  10. doi Optimal assessment of response in ovarian cancer
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Ann Oncol 22:viii49-viii51. 2011
    ....
  11. ncbi New targets and non-cytotoxics in ovarian cancer
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 17:x247-50. 2006
  12. ncbi Response evaluation: beyond RECIST
    E A Eisenhauer
    NCIC Clinical Trials Group, Queen s University, Kingston, ON, Canada
    Ann Oncol 18:ix29-32. 2007
  13. ncbi Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
    E A Eisenhauer
    NCIC Clinical Trials Group, Kingston Ontario, Canada
    Invest New Drugs 8:283-7. 1990
    ..We conclude menogaril is active in breast cancer and recommend that because it can be delivered in high doses orally, future trials in this disease should focus on intense oral schedule...
  14. ncbi High-dose chemotherapy: is it standard management for any common solid tumor?
    M Macneil
    Queen s University, Kingston, Ontario, Canada
    Ann Oncol 10:1145-61. 1999
    ..We speculate about the differences in philosophical approaches to cancer treatment which might contribute to early acceptance of novel therapies in the absence of adequate randomized data...
  15. ncbi Systemic treatment policies in ovarian cancer: the next 10 years
    J J Biagi
    Kingston Regional Cancer Centre, Kingston, ON, Canada
    Int J Gynecol Cancer 13:231-40. 2003
    ..New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned...
  16. ncbi Novel endpoints and design of early clinical trials
    W R Parulekar
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    Ann Oncol 13:139-43. 2002
  17. ncbi Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    Ann Oncol 10:9-15. 1999
    ..If our understanding of molecular basis of aggressive disease improves, new treatments may evolve which will turn "prognostic" indicators into "predictive" indicators, allowing selection of treatment by molecular subset...
  18. ncbi Update in methodology and conduct of cancer clinical trials
    P Therasse
    EORTC Data Center, Av E Mounier, 83 box11, 1200 Brussels, Belgium
    Eur J Cancer 42:1322-30. 2006
    ..There is much less academic research conducted in Europe, there is a lot of discrepancy and inconsistency in the implementation of the directive across member states and there is no apparent direct benefit for the patients...
  19. ncbi A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
    A Belch
    Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
    Ann Oncol 18:116-21. 2007
    ..We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma...
  20. ncbi Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials
    M Fung Kee Fung
    Department of Obstetrics and Gynaecology, University of Ottawa, ON, Canada
    Eur J Gynaecol Oncol 23:104-10. 2002
    ..To evaluate the chemotherapeutic options for women with recurrent epithelial ovarian cancer who have received platinum-based chemotherapy...
  21. ncbi Clinical trials in ovarian carcinoma: study methodology
    J B Vermorken
    Department of Oncology, University Hospital Antwerp, Edegem, Belgium
    Ann Oncol 16:viii20-viii29. 2005